1 / 11

NEW INSIGHT INTO BIOMARKERS OF HYPERTENSIVE CARDIAC AND VASCULAR REMODELING

cima. NEW INSIGHT INTO BIOMARKERS OF HYPERTENSIVE CARDIAC AND VASCULAR REMODELING. N. López-Andrés (Pamplona and Nancy). CIC Nancy. InGenious HyperCare Integrating genomics, clinical research and care in hypertension Genetic, genomics and proteomics of transition

lexi
Download Presentation

NEW INSIGHT INTO BIOMARKERS OF HYPERTENSIVE CARDIAC AND VASCULAR REMODELING

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. cima NEW INSIGHT INTO BIOMARKERS OF HYPERTENSIVE CARDIAC AND VASCULAR REMODELING N. López-Andrés (Pamplona and Nancy) CIC Nancy InGenious HyperCare Integrating genomics, clinical research and care in hypertension Genetic, genomics and proteomics of transition from hypertension to heart failure Excellence in phenotyping. Circulating markers of LV growth and dysfunction FIMA Pamplona

  2. Heart failure LV hypertrophy Stage C * Stage A Stage B Classification in the different stages of HF according AHA/ACC guidelines * (Hunt S et al. Circulation 2001;104:2996-3007) CLINICO-PATHOLOGICAL EVOLUTION IN HYPERTENSIVE HEART DISEASE High blood Structural remodeling (Díez J et al, Nature Clin Pract Cardiovasc Med 2005;2:209-216)

  3. STRUCTURAL BASIS OF MISADAPTIVE MYOCARDIAL REMODELING IN HYPERTENSIVE HEART DISEASE Interstitial fibrosis Vessel wall remodeling Cardiomyocyte hypertrophy Cardiomyocyte apoptosis

  4. CT-1 LIF OSM • IL-6 family gp130 LIF-R CARDIOTROPHIN -1 (CT-1) • 21.5 KDa • 201 aa • Gen CTF1 (5211 pb.) • “Hypertrophic factor” in cardiomyocytes • Expression in heart, skeletal muscle, lung, kidney, stomach, liver, adipose tissue and atherosclerotic tissue (endothelial cells)

  5. CT-1 CT-1 López B et al. J Hypertens 2005 Myocardial fibrosis López N et al., in preparation CT-1 AND MYOCARDIAL FIBROSIS López N et al., in preparation

  6. LV growth and dysfunction Ventricular-Vascular uncoupling Vascular remodeling Vascular alterations CT-1: NEW INSIGHTS CT-1 Myocardial remodeling

  7. CT-1 CT-1 +/- CT-1 EFFECTS ON VASCULAR MORPHOLOGY AND FUNCTION 6 weeks In vivo EXPERIMENTAL DESIGN In vitro VSMC +/- CT-1 EFFECTS AND REGULATION Ex vivo AORTA

  8. SUMMARY Ang II Aldo Stretch CT-1 VSMC proliferation and hypertrophy Secretory phenotype MMPs activity Collagen Elastin Fibronectin WALL THICKNESS AND ARTERIAL STIFFNESS

  9. To characterize the potential pathophysiological role of CT-1 not just in essential hypertension but also in the MetS, obesity and hyperaldo To explore the association of plasma CT-1 not just with cardiac phenotype but also with vascular phenotype Leuven Nancy Brescia Milan Pamplona NEW DEVELOPMENTS OF CT-1 IN THE CONTEXT OF THE NoE Ingenious HyperCare

More Related